Avipep

What Avipep does

Avipep Therapeutics is a clinical-stage biotechnology company developing proprietary Avibody™-drug conjugates for patients with relapsed and refractory cancer. Founded in 2005, the company is headquartered in Cambridge, Massachusetts (One Broadway, Cambridge, MA 02142), with a secondary research operation in Parkville, Victoria, Australia (343 Royal Parade, Parkville VIC 3052), operating through its legal entity Avipep Pty Ltd. The company targets the oncology ADC (Antibody-Drug Conjugate) market with an explicit focus on patients who have failed prior lines of therapy, where toxicity and tumor penetration of existing antibody-based therapies remain meaningful clinical limitations.

The company's core technology is the Avibody™ platform — small, stable, high-avidity antibody-derivatives (nanobody-like fragments) engineered as a next-generation ADC format. Avibodies can be derived from or reformatted from existing intact antibodies and then conjugated with potent cytotoxic drug payloads. Per the company's own clinical disclosures, Avibodies demonstrate superior biodistribution and tumor penetration compared with traditional intact IgG antibodies, with rapid tumor penetration, durable intratumoral persistence measured in weeks, and rapid systemic clearance measured in hours — a pharmacokinetic profile engineered to enable potent payload delivery with reduced off-target toxicity relative to conventional ADCs. The company has advanced candidates into Phase I/II clinical trials in cancer patients.

Avipep operates a licensing and collaboration business model, targeting pharmaceutical partners for out-licensing and co-development of Avibody™-drug conjugates. Revenue mechanics (where present) flow through upfront payments, development and commercial milestones, and royalties on net sales. The company pursues scientific positioning through conference presentations (notably a World ADC Conference poster, October 2019) and direct outreach via its "Partnering" and "Contact Us" web pages. Leadership consists of CEO Owen Dempsey (MBA) and CSO Peter Hudson (PhD). Ascend Biopharmaceuticals Ltd appears alongside Avipep in the company's branding, suggesting a strategic or co-development relationship, though specific terms are not disclosed.

Name

Avipep

Legal name

Avipep Pty Ltd

Website

https://avipep.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Avipep Therapeutics is a clinical-stage biotechnology company developing proprietary Avibody™-drug conjugates for relapsed and refractory cancer patients, licensing its next-generation ADC platform to pharmaceutical partners via operations in Cambridge, MA and Parkville, Australia.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Antibody-Drug Conjugates

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Antibody-drug conjugates
• Oncology therapeutics
• Biopharmaceutical licensing
• Antibody engineering platform
• Cancer drug development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and Collaboration Revenue: Avipep develops its proprietary Avibody™-drug conjugate platform and pipeline through clinical stages, then out-licenses or co-develops assets with pharmaceutical partners. Revenue streams include upfront payments, milestone payments, and royalties on net sales from licensing deals. The company explicitly invites collaboration and license inquiries on its website.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Avipep Therapeutics develops proprietary Avibody™-drug conjugates — small, stable, high-avidity antibody-derivative fragments engineered as a next-generation Antibody-Drug Conjugate (ADC) platform — for the treatment of relapsed and refractory cancers. The company advances its pipeline through clinical development and out-licenses or co-develops assets with pharmaceutical partners.

Product overview

Avipep Therapeutics is developing a single proprietary technology platform centered on Avibody™-drug conjugates for cancer treatment. Avibodies are novel antibody-derivatives that offer superior tumor penetration and persistence compared to traditional intact IgG antibodies. The technology can be rapidly reformatted from existing intact antibodies to create targeted cancer therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Avibodies: Proprietary Avibody™-drug conjugates platform technology for next-generation ADCs (Antibody-Drug Conjugates)

Products and services

• Avibody™-drug Conjugates Proprietary Avibody™ molecules — small, stable, high-avidity antibody-derivatives with superior biodistribution and tumor penetration versus traditional intact IgG antibodies — conjugated to cytotoxic drug payloads to deliver highly potent payloads with reduced off-target toxicity. Intended for licensing and co-development by pharmaceutical partners and for eventual treatment of cancer patients with relapsed and refractory disease.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Ascend Biopharmaceuticals LtdminorStrategic or Co-development PartnerAscend Biopharmaceuticals Ltd appears alongside Avipep on the company logo/branding, suggesting a collaborative or strategic relationship. No specific co-development or licensing terms are detailed on the primary website.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• ImmunoGen: Pioneer in ADC development with approved products and a pipeline of next-generation ADCs. Closely comparable ADC platform business with licensing and partnered assets in oncology.
• Mersana Therapeutics: Clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) targeting oncology. Direct competitor to Avipep in next-generation ADC technology for cancer treatment.
• Pyxis Oncology: Clinical-stage ADC and antibody-therapeutic developer focused on difficult-to-treat cancers. Comparable in stage and therapeutic focus to Avipep's Avibody platform.

Emerging players

• CytomX Therapeutics: Clinical-stage developer of masked, conditionally activated antibody therapeutics including Probody-drug conjugates. Comparable as a platform-based antibody-conjugate developer targeting oncology.
• Bolt Biotherapeutics: Clinical-stage developer of immune-stimulating ADCs (ISACs). Comparable in being a small-cap, clinical-stage ADC platform company targeting oncology.
• Heidelberg Pharma: Clinical-stage ADC developer using amanitin-based payloads with proprietary linker technology. Comparable as a smaller-cap ADC platform company focused on next-generation oncology therapeutics.
• Araris Biotech: Pre-clinical/early-clinical ADC company with a proprietary linker technology for site-specific payload conjugation. Comparable as an emerging ADC platform developer targeting oncology.
• ProfoundBio: Clinical-stage ADC developer with proprietary linker-payload technologies and oncology pipeline. Comparable emerging ADC platform company in size and clinical stage.

Broad incumbents

• Daiichi Sankyo: Developer of Enhertu and Datroway ADCs and a leading force in the ADC space. Its DXd ADC platform is a direct technology competitor to Avibody-drug conjugates in oncology.
• Seagen: Established ADC leader (now part of Pfizer) with multiple approved ADC products and a deep pipeline. A broad incumbent whose ADC platform competes with Avibody-DCs in oncology indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avipep